Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940162 | 0.96 | CHEK1 (0.81) | CHEK1HRH3HRH2HRH1RAF1 | |
| SCHEMBL6594476 | 0.95 | CHEK1 (0.79) | CHEK1HRH3HRH2HRH1RAF1 | |
| Hydrochloric Acid SCHEMBL4503506 | 0.94 | CHEK1 (0.78) | CHEK1HRH3HRH2HRH1RAF1 | |
| SCHEMBL7211233 | 0.94 | CHEK1 (1.00) | CHEK1HRH3HRH2HRH1RAF1 | |
| Hydrochloric Acid SCHEMBL4497841 | 0.91 | CHEK1 (0.74) | CHEK1HRH3HRH2HRH1AURKA | |
| Hydrochloric Acid SCHEMBL4495599 | 0.91 | CHEK1 (0.74) | CHEK1HRH3HRH2HRH1AURKA | |
| SCHEMBL7205566 | 0.87 | CHEK1 (0.68) | CHEK1MAP2K1SRCKDRPDGFRB | |
| SCHEMBL7206444 | 0.87 | CHEK1 (0.77) | CHEK1HRH3RAF1MAP2K1AURKA | |
| Hydrochloric Acid SCHEMBL7206387 | 0.86 | CHEK1 (0.67) | CHEK1MAP2K1SRCKDRPDGFRB | |
| SCHEMBL7210165 | 0.85 | CHEK1 (0.67) | CHEK1HRH3AURKAAURKBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | claimed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | claimed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | claimed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | claimed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | claimed |
| US-20230115252-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | CHEK1 881/4885HRH3 1465/4885HRH2 3297/4885 |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | GSK3A, GSK3B, PSEN1 | CHEK1 1014/4885HRH3 1080/4885HRH2 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.